论文部分内容阅读
目的探讨奥沙利铂联合卡培他滨治疗进展期胃癌的临床疗效。方法选取我院进展期胃癌患者50例,收治时间在2015年2月至2015年12月期间,并将进展期胃癌患者随机分为两组(观察组和对照组),对照组进展期胃癌患者采用ECF方案治疗,观察组进展期胃癌患者采用奥沙利铂联合卡培他滨治疗。结果观察组进展期胃癌患者治疗后的不良反应发生率和总有效率显著优于对照组(P<0.05)。结论奥沙利铂联合卡培他滨治疗进展期胃癌具有良好的效果,不仅能增加进展期胃癌患者的总有效率,还能减少不良反应发生率。
Objective To investigate the clinical efficacy of oxaliplatin plus capecitabine in the treatment of advanced gastric cancer. Methods Fifty patients with advanced gastric cancer in our hospital were enrolled in this study. The duration of treatment was from February 2015 to December 2015. Patients with advanced gastric cancer were randomly divided into two groups (observation group and control group). Patients in the control group with advanced gastric cancer Treatment with ECF regimen, observation group advanced gastric cancer patients with oxaliplatin combined with capecitabine treatment. Results The incidence of adverse reactions and total effective rate of patients with advanced gastric cancer after treatment in the observation group were significantly better than those in the control group (P <0.05). Conclusion Oxaliplatin combined with capecitabine has a good effect on advanced gastric cancer, which can not only increase the total effective rate of patients with advanced gastric cancer, but also reduce the incidence of adverse reactions.